Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide. SARS-CoV-2-IN-13 is more stable than niclosamide in human plasma and liver S9 enzymes assay. SARS-CoV-2-IN-13 can improve bioavailability and half-life when administered orally. SARS-CoV-2-IN-13 is a potent SARS-CoV-2 inhibitor with an IC 50 of 0.057 μM [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 51.00 | |
5 mg | In stock | $ 122.00 | |
10 mg | In stock | $ 197.00 | |
25 mg | In stock | $ 397.00 | |
50 mg | In stock | $ 589.00 | |
100 mg | In stock | $ 843.00 | |
500 mg | In stock | $ 1,730.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 133.00 |
Description | SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide. SARS-CoV-2-IN-13 is more stable than niclosamide in human plasma and liver S9 enzymes assay. SARS-CoV-2-IN-13 can improve bioavailability and half-life when administered orally. SARS-CoV-2-IN-13 is a potent SARS-CoV-2 inhibitor with an IC 50 of 0.057 μM [1]. |
Molecular Weight | 327.12 |
Formula | C13H8Cl2N2O4 |
CAS No. | 56961-10-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (343.9 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SARS-CoV-2-IN-13 56961-10-5 Microbiology/Virology SARS-CoV inhibitor inhibit